Quince Therapeutics, Inc.

Quince Therapeutics, Inc. is a biotechnology company that previously focused its development activities on treating rare diseases using a patient's own biology. The company's proprietary AIDE technology platform is an innovative drug/device combination designed to automatically encapsulate a drug into a patient's own red blood cells. This technology aimed to leverage the characteristics of red blood cells for drug delivery, potentially offering benefits such as improved safety and tolerability, enhanced tissue biodistribution, reduced immunogenicity, and prolonged circulating half-life. The AIDE platform was designed to apply to a wide range of small or large molecule drugs and biologics. The company's lead asset, eDSP, utilized the AIDE technology to encapsulate DSP into a patient's red blood cells. In January 2026, Quince Therapeutics completed its pivotal Phase 3 NEAT clinical trial, which evaluated eDSP for the treatment of A-T, a rare pediatric neurodegenerative disease. The primary endpoint of the NEAT study, which measured the change from baseline to the last efficacy visit at month six using the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo, did not achieve statistical significance. Consequently, eDSP does not appear to be an effective treatment for A-T, and the company will not continue its development for this or other therapeutic indications. Quince Therapeutics currently has no other product candidates and lacks sufficient resources to pursue further research and development activities. The company is focused on preserving cash while evaluating strategic alternatives. On February 9, 2026, LifeSci Capital was engaged as the exclusive financial advisor to assist with restructuring activities and the evaluation of strategic alternatives.